



OBESITY PHARMACOTHERAPY: PHARMACIST'S ROLE IN LIFESTYLE AND DRUG MANAGEMENT

Dr.Monika.P*

Assistant Professor, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, Tamilnadu, India 600117.

ABSTRACT

Obesity is a multifactorial, complex disease, which plays an important role in creating a burden of various chronic conditions in the world, including diabetes type 2, cardiovascular disease, high blood pressure, and some types of cancer. Although lifestyle change is the main intervention in obesity control, the pharmacotherapy becomes increasingly important in patients with body mass index (BMI) of 30 kg/m² and above or 27 kg/m² and comorbid conditions. The pharmacists can be at the center of the management of obesity because they are the most accessible, have knowledge in managing medication and can lead the patients through changes of lifestyle. This paper will examine pharmacists' role in obesity pharmacotherapy with regard to their role in medication management, patient education, and personalized care. It points out as well the significance of the multidisciplinary approach that includes diet, exercise, and behavioral interventions as well as pharmacological treatments. Pharmacists play an important role in mitigating the problem of obesity in the world and enhancing the long-term health outcomes of patients by improving patient adherence and optimizing treatment regimens.

Keywords: Obesity, Pharmacotherapy, Pharmacist's Role, Weight Management, Lifestyle Modification.

INTRODUCTION

Obesity is a multifactorial and complicated disease, which entails the excessive build-up of fat, which is a major problem in endangering the health of the populace in any given society. It is linked to a higher risk of a number of chronic ailments, such as type 2 diabetes mellitus, heart disorders, blood pressure, cholesterolemia, and some forms of cancer. The increased prevalence of obesity in

the world today has raised the concern about preventive and curative measures to the extent that pharmacotherapy has become a viable approach in controlling obesity especially in situations where lifestyle changes have failed[1–8]. Although lifestyle interventions including nutrition, exercise, and behavior therapy are the primary methods of treating obesity in patients, the use of the pharmacological methods is becoming a crucial complement, particularly in patients with a body mass index (BMI) of 30kg/m² or higher, or with a BMI 27kg/m² or higher, and comorbidities. The role of pharmacists in the management of obesity is increasing because most of them are the most readily available healthcare provider and they play a significant role in lifestyle change as well as administration of anti-obesity drugs. The pharmacists are in the best position to evaluate the appropriateness of pharmacotherapy in patients, educate on appropriate medication intake, monitor possible side effects, and encourage adherence to treatment schedules. They are also crucial in advising

Access this article online

Home page:
<http://ijppdr.com/>

Quick Response
code



Received:27.02.2026 Revised:12.03.2026 Accepted:14.03.2026

Corresponding Author

Dr.Monika.P

Email: monikapeter750@gmail.com

patients on behavioral modifications that can be used together with pharmacological management strategies like dietary modifications, physical activities, and stress management measures. The knowledge of pharmacists in medication management also enables them to follow complicated drug regimens and provide safe and efficient treatment programs, considering such aspects as drug interactions, comorbidity, and patient-related needs. As newer anti-obesity medications that inhibit different pathways used by the body to regulate appetite, fat absorption, and energy balance have emerged, the part of pharmacists in obesity treatment has become more noticeable. These drugs, including GLP-1 receptor agonists, orlistat and sympathomimetic drugs are extra devices to realize weight reduction and enhance health results in the long run. Nevertheless, the pharmacotherapy cannot be considered as a standalone treatment approach that should be used instead of a more serious, individualized treatment plan that incorporates lifestyle interventions. Pharmacists work with other health professionals, such as dietitians, physicians, and behavioral therapists in providing holistic care, which provides the physical, psychological, and social dimensions of obesity. Moreover, pharmacists play a major role in the safety and efficacy of obesity drugs, follow-up evaluation to assess weight loss, and modification of treatment plans. Although the issues of obesity management are quite important, the role of the pharmacists cannot be underestimated in the process of maximizing the treatment results, improving patient education, and facilitating long-term health and wellness [9–11].

Global Burden of Obesity

The world has become a center of obesity with alarming numbers, as it is one of the greatest public health problems of the 21st century. Obesity is described as fat excess which may deteriorate health and has been associated with many chronic illnesses such as cardiovascular disease, type 2 diabetes, high blood pressure, stroke and some cancers. Obesity has been on the rampage all over the world and as per the world health organization (WHO) it has been estimated that about 650 million adults in the world are obese [12,13]. It is a serious social, economic, and health-related impact of this rampant epidemic because it puts a massive burden on healthcare systems and causes premature deaths. The fast-growth rate of obesity can be associated with a set of factors, the alteration in nutrition, the decrease in physical activity, urbanization, and the socio-economic inequality. Eating foods that contain high calories and low nutrients and unhealthy lifestyles have worsened the situation especially in high income nations where processed foods are easy to access. Nonetheless, obesity is not limited to poor economic countries, but is developing at an alarming rate in developing and middle-income countries as well,

and usually in tandem with the changes toward urbanization and Westernized diets. The economic cost of obesity is immense, as there is direct healthcare expenditures that entail the cost of obesity related diseases and indirect cost of obesity that is because of lost productivity, absenteeism and premature disability claims. Indeed, it is believed that the expenses to treat obesity take a large percentage of the total health spending in the world. Also, the societal consequences of obesity are immense, impacting the quality of life and the mental illnesses as well as productivity of people. Obese individuals also face stigma, discrimination and lack of employment opportunities among other factors that contribute to societal inequalities. The effect of obesity on health outcomes is of particular concern since it has a great impact on the development of various comorbidities resulting in earlier death. The most usual causes of death in obese patients include cardiovascular diseases, including heart attacks and strokes, and type 2 diabetes, which is becoming a global epidemic in its turn due to insulin resistance. This increasing crisis is not spared in children and adolescents with the prevalence of obesity in childhood soaring to alarming levels and childhood obesity is resulting in the development of obesity related diseases at earlier age. Obesity has also been experienced through the drain on the healthcare resources, with more and more hospitals and healthcare facilities becoming overstretched due to the growing number of procedures to deal with obesity and obesity related disorders. The global weight menace, like obesity, should be handled in a multi-tiered effort with prevention, health education, and access to healthy food, and changes in lifestyle. Also, nations and medical practitioners should focus more on early screening and treatment as a way of reducing the health risks in the long run and alleviating the burden of this ever-increasing epidemic [14,15].

Cardiometabolic Risks

Cardiometabolic risks are a set of conditions and practices that place people at a significant risk of developing cardiovascular malady (CVD) and metabolic sick conditions such as type 2 diabetes, hypertension, and dyslipidemia. These are all risk factors that are closely related and in most cases linked to unhealthy lifestyle habits like poor diet, physical inactivity, smoking and excessive alcohol drinking [16–18]. At the core of cardiometabolic risks lie the notions of metabolic syndrome which is defined by abdominal obesity, insulin resistance, high blood pressure, elevated levels of triglycerides, and low levels of high-density lipoprotein (HDL) cholesterol. Persons with metabolic syndrome are at significantly increased risk of heart disease, stroke, and diabetes. Excessive fat and obesity, especially abdominal fat, are highly important in the occurrence of these states as it facilitates inflammation, lipid metabolism, and insulin resistance. Obesity has become widely prevalent

in most parts of the world thus making cardiometabolic diseases very widespread thus adding to the burden of disease in the world. Moreover, genetic factors, age, and gender are also the reasons why an individual is at risk of cardiometabolism, yet lifestyle factors are regarded as the most adjustable. These risk factors could also need regulation by pharmacological methods, such as hypertension, dyslipidemia, and insulin resistance medications. In prevention and better health outcomes in the long term, early detection and intervention play a critical role in the mitigation of cardiometabolic diseases. The implementation of preventive practices of at-risk populations and public health interventions to facilitate a healthier lifestyle play a major role in reducing the increasing cardiometabolic risk of the global population [17,19].

Pathophysiology of Obesity

Obesity pathophysiology is complicated and a combination of genetic, environmental, metabolic, and behavioral processes that result in excess fat in the body. Fundamentally, obesity is a consequence of energy intake versus energy expenditure in which the body is taking in more calories than it is using up, which causes the body to store the unused energy as fatty tissues [20–22]. The main aspect of this process is the dysregulation of various physiological systems, among them central nervous system, adipose tissue, and endocrine system. The hypothalamus is instrumental in sustaining the energy balance, satiety, and hunger. Moreover, when excess body fat damages other organs like the heart and liver, other conditions like hypertension, fatty liver disease, and high cardiovascular risks are also promoted. Obesity also depends on the pathophysiology of genetic predisposition, in which some genetic variations may influence the body to process and store fat, and the rest of the environment factors, including bad diet, exercise and socioeconomic status, have a significant role in influencing obesity. In general, obesity is a complex disease that is caused by an energy homeostasis dysregulation, insulin resistance, inflammation, and hormonal disturbances, which collectively predispose an individual to a variety of chronic illnesses and decrease their health outcomes [23,24].

Energetic Imbalance and Hormonal Control.

The pathophysiology of obesity and other metabolic disorders consists of energy imbalance and hormonal regulation. Energy balance in the body is achieved by the interaction of complex interplay between the energy taken in by food and the energy used by the body basal metabolic rate, physical activity, and thermogenesis. In cases where energy consumption is more than the amount of energy used, the excess stored is stored as adipose tissue, which results in weight gain, and ultimately obese conditions are experienced [25–27].

Hormones are essential in controlling appetite and energy balance and the hormones that are important in this process include leptin, ghrelin, insulin, and cortisol. Insulin resistance can also take place in obesity where the cells of the body become less responsive to insulin resulting in an increase in the levels of insulin in the body and fats. Also, the hormone cortisol, a stress hormone, may affect the energy balance by increasing fat storage, especially in the belly. Prolonged stress causes a rise in cortisol which in its turn may expand appetite and cause deposition of fat in the visceral areas. Thyroid hormones, thyroxine (T4) and triiodothyronine (T3) also contribute to energy expenditure through the regulation of the metabolic rate. The thyroid can also change its energy regulation in obesity and thus metabolic rate changes and results in weight gain. In general, the issue of hormonal balance of energy is complicated with a complex feedback loop comprising of hormones controlling the appetite, fat storage and energy expenditure. Obesity development and progress are caused by alterations in these hormonal cues including leptin resistance, insulin resistance, and modifications in ghrelin and cortisol. Such hormonal imbalances promote overeating, fat storage and predisposes him or her to related diseases such as type 2 diabetes, heart diseases, and metabolic syndrome [28–30].

Pharmacotherapy of Obesity

Obesity pharmacotherapy is an inseparable part of the multifaceted mechanism of obesity treatment, especially in cases when the person has not undergone enough weight loss due to lifestyle intervention. Drugs are usually referred to in case a patient weighs 30 kg/m² or more, 27 kg/m² with related comorbidities like type 2 diabetes, hypertension or dyslipidemia [31,32]. Pharmacotherapy is meant to achieve a decrease in weight, better metabolic status, and lessening of comorbidities associated with obesity, such as cardiovascular disease and type 2 diabetes. Anti-obesity drugs have a number of classes that act in differing ways to suppress appetite, burn more energy or limit the intake of fat. Orlistat, liraglutide, phentermine-topiramate, and naltrexone-bupropion are the most popular anti-obesity drugs. Orlistat is a lipase blocker which is used to lower calorie level by decreasing intake of dietary fats in the intestines. It is the sole OTC weight loss drug, and usually is taken in combination with a low-fat diet. Nonetheless, the side effects of orlistat include diarrhea and oily bowels that reduce its tolerance in some patients. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptors agonist that is used in the management of type 2 diabetes and weight to increase satiety, slow down gastric emptying, and increase insulin sensitivity. It has also been demonstrated to go a long way in minimizing body weight when used together with changes in the lifestyle. Phentermine-topiramate is a blend of two drugs phentermine (a sympathomimetic) that suppresses

appetite and topiramate (anticonvulsant) that has been found to decrease appetite and increase the amount of energy expended. Obesity pharmacotherapy should be closely monitored on the side effects and long-term safety because several of them are contraindicated, such as psychiatric disorders or heart problems. Finally, the choice of pharmacotherapy should be personal, which is why it is preferable to consider the overall health of a patient, comorbid conditions, and his/her preferences. Furthermore, although these drugs may aid in weight loss, long term weight loss and management will entail continuous assistance, training and lifestyle adjustment to avoid weight gain and ensure better health results [5, 7, 33, 34].

Weight Management Programs that are Pharmacist-led

Weight management programs delivered by pharmacists have come to occupy an undeniable role in the healthcare system as a cost-effective and evidence-based intervention to counteract obesity and comorbidities. The pharmacist is well equipped to assume a central role in weight management as a highly trained medical professional because of his or her knowledge in medication management, patient counseling, and chronic disease management. Some of these programs can be centered on the promotion of healthy lifestyle changes, such as dietary changes, physical activity, and behavioral interventions, and the needs in pharmacotherapy can be addressed as well in case such intervention is required [7,35,36]. One of the main aspects of pharmacist-led programs is that they offer individual and close counseling to the patients so that they can come up with realistic and achievable goals of losing weight and acquiring healthy habits. Pharmacists are trained in examining medication regimens and reviewing possible drug interactions of patients, and pharmacotherapy of weight loss is prescribed accordingly. They are able to monitor the efficiency of anti-obesity drugs, inform patients on how to use them and give them tips on how to deal with side effects. Moreover, the pharmacists are empowered to screen the patients in the comorbidities of obesity like diabetes type 2, hypertension, and dyslipidemia, and the weight management program would be customized to meet the special needs of the patient. By developing a continuous monitoring and follow-up,

pharmacists are able to measure progress, give encouragement and revise treatment plans whenever necessary in order to improve the process of losing weight. Such a teamwork approach makes sure patients are well taken care of to cover the entire aspect of obesity and weight loss. The support of pharmacist role in weight management is evidenced by increasing amount of evidence that demonstrates that they can take part to improve the outcomes of patients, to reduce the risk of the development of some chronic illnesses and to eventually aid in reducing healthcare expenditures by avoiding complications associated with obesity. In general, the weight management programs delivered by pharmacists provide an integrated patient-centered intervention that enables individuals to gain control over their health, sustainably lose weight, and decrease the role of obesity in personal and national healthcare [36,37].

Selection of patients and risk arrangements.

Risk assessment and patient selection are essential parts of an effective weight management program especially in regard to the management of obesity where a holistic approach is required to establish the optimal course of action to be applied on each patient. A careful risk assessment consists in assessing the physical health and behavioral or psychological conditions of the patient that might influence his capacity to effectively manage his weight. The measurements of the waist circumference to determine the visceral fat are also relevant aspects of this assessment because abdominal obesity is a clearer predictor of cardiovascular disease and metabolic disorders compared to the one based on BMI [38–40]. Besides, screening the obesity-related comorbidities like type 2 diabetes, hypertension, dyslipidemia, and sleep apnea is also a part of the assessment to have an additional impact on the treatment decisions. There are also risk factors like age, gender, and ethnicity that contribute to the emergence of the obese and the accompanying diseases, and some people are more susceptible to complications. The intervention is designed to optimize the success of weight loss and minimize the risk of developing obesity-related complications by selecting the patients carefully and thoroughly screening them in terms of risk factors, which will eventually be beneficial to the patient outcomes and quality of life [41,42].

Table 1: Common Pharmacological Agents Used in Obesity Management

Drug	Drug Class	Mechanism of Action	Common Side Effects	Clinical Benefit
Orlistat	Lipase inhibitor	Inhibits gastric and pancreatic lipases, reducing fat absorption in the intestine	Oily stools, diarrhea, flatulence	Decreases caloric absorption and promotes weight loss
Liraglutide	GLP-1 receptor agonist	Increases satiety, slows gastric emptying, improves insulin sensitivity	Nausea, vomiting, headache	Reduces appetite and improves glycemic control

Phentermine– Topiramate	Sympathomimetic + anticonvulsant	Suppresses appetite and increases energy expenditure	Dry mouth, insomnia, dizziness	Significant weight reduction
Naltrexone– Bupropion	Opioid antagonist + antidepressant	Acts on CNS reward pathways to reduce hunger and cravings	Nausea, headache, insomnia	Helps control appetite and emotional eating
Semaglutide	GLP-1 receptor agonist	Enhances satiety and reduces food intake	Gastrointestinal discomfort, nausea	Effective long-term weight loss

Table 2: Key Pharmacist Interventions in Obesity Management

Pharmacist Role	Description	Impact on Patient Outcomes
Patient Assessment	Evaluating BMI, waist circumference, comorbidities, and medication history	Identifies appropriate candidates for pharmacotherapy
Medication Counseling	Educating patients on correct use of anti-obesity medications	Improves medication adherence
Monitoring Drug Therapy	Monitoring weight changes, side effects, and drug interactions	Ensures safe and effective treatment
Lifestyle Counseling	Advising on diet, exercise, and behavioral changes	Supports sustainable weight loss
Adverse Effect Management	Identifying and managing medication side effects	Improves patient safety
Follow-up and Support	Regular monitoring and motivation through follow-up visits	Enhances long-term treatment success

Figure 1: Energetic Imbalance and Hormonal Control in Obesity



Figure 2: Patient Selection and Risk Assessment in Obesity Management



Lifestyle Modification Counseling

Lifestyle modification counseling is one of the milestones of a successful weight management program because it assists individuals to make sustainable alterations in their diet, exercise and behavior in order to lose weight in the long run and maintain the health. Lifestyle modification counseling aims mostly at empowering the patient with the knowledge, skills and desire to make better healthier decisions that would support his or her weight management goals [43–45].

CONCLUSION

Obesity is a complex chronic condition with significant global health impact, contributing to

comorbidities such as type 2 diabetes, cardiovascular disease, hypertension, and dyslipidemia. Effective management requires a multidisciplinary approach combining lifestyle modification, pharmacotherapy, and continuous patient monitoring. While dietary changes, physical activity, and behavioral therapy remain the foundation, they may be insufficient in certain patients. In such cases, anti-obesity medications—such as lipase inhibitors, GLP-1 receptor agonists, and combination therapies—play an important role in promoting weight loss and improving metabolic outcomes. However, their use requires careful patient selection, monitoring, and management of potential adverse effects to ensure safety and efficacy.

REFERENCES

1. Kheniser K, Saxon DR, Kashyap SR. Long-Term Weight Loss Strategies for Obesity. *J. Clin. Endocrinol. Metab.*, 106(7), 2021, 1854–1866.
2. Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. *Diabetes Obes. Metab.* 24(Suppl. 2), 2022, 44–54.
3. Yazıcı D, Yapıcı Eser H, Kızılcı S, Sancak S, Sezer H, Uygur M, et al. Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. *Obes. Facts*, 16(2), 2023, 149–163.
4. Ansari S, Khoo B, Tan T. Targeting the incretin system in obesity and type 2 diabetes mellitus. *Nat. Rev. Endocrinol.*, 20(8), 2024, 447–459.
5. Contreras F, Al-Najim W, Le Roux CW. et al. Health Benefits beyond the Scale: The Role of Diet and Nutrition During Weight Loss Programmes. *Nutrients*, 16(21), 2024, 3585.
6. Chung YL. Effective and appropriate use of weight loss medication in pediatric obesity: a narrative review. *J. Yeungnam Med. Sci.*, 41(2), 2024, 158–165.
7. Schauer PR, Rothberg AE. Point-Counterpoint Debate: Surgery vs Medical Treatment for the Management of Obesity. *J. Clin. Endocrinol. Metab.*, 110, 2024,
8. Minnetti M, Barazzoni R, Batsis JA, Busetto L, Yumuk V, Poggiogalle E, et al. The Integration of Lifestyle Modification Advice and Diet and Physical Exercise Interventions: Cornerstones in the Management of Obesity with Incretin Mimetics. *Obes. Facts*, 18, 2025, 1–16.
9. Ahmed R, Tamim T. Enhancing Medication Safety: The Role of Community and Hospital Pharmacists in Modern Healthcare Systems. *Radinka J. Health Sci.*, 2(3), 2025, 328–355.
10. Al Meslamani AZ. Before you start: the safety of SGLT2 inhibitors for anti-obesity treatment. *Expert Opin. Drug Saf.*, 2025,
11. Tchang B, Broffman L, Manalac R, Chai S, Samonas N, Barnes M, et al. Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study. *Obesity*, 2025,
12. Gan Y-Y, Luo Y-D, Zhai L, Huo R-R, Dai X, Liao Q. et al. Temporal trends, associated risk factors and longitudinal cardiovascular outcomes of body roundness among middle-aged and older Chinese adults: from the China Health and Retirement Longitudinal Study 2011-2018. *Front. Nutr.* 12, 2025, 1515067.
13. Ullah MI, Tamanna S. Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies. *Medicines*, 12(3), 2025, 19.
14. Verma M, Kapoor N, Senapati S, Singh O, Bhadoria AS, Khetarpal P, et al. Comprehending the Epidemiology and Aetiology of Childhood Obesity: Integrating Life Course Approaches for Prevention and Intervention. *Diabetes Ther.* 16, 2025, 1177–1206.
15. Qiu R, Song R, Wu X, Feng J, Yang Y, Pan Y, et al. From awareness to adoption: a panoramic perspective on the utilization of Internet Medical Services among Chinese patients with chronic disease. *BMC Health Serv. Res.*, 25, 2025,
16. Berisha H, Hattab R, Comi L, Giglione C, Migliaccio S, Magni P. et al. Nutrition and Lifestyle Interventions in Managing Dyslipidemia and Cardiometabolic Risk. *Nutrients*, 17(5), 2025, 776.
17. Hamooya BM, Siame L, Muchaili L, Masenga SK, Kirabo A. et al. Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches. *Front. Nutr.*, 12, 2025, 1661603.
18. Direksunthorn T. Sleep and Cardiometabolic Health: A Narrative Review of Epidemiological Evidence, Mechanisms, and Interventions. *Int. J. Gen. Med.*, 18, 2025, 5831–5843.

19. Valerio G, Di Bonito P, Calcaterra V, Cherubini V, Corica D, De Sanctis L, et al. Cardiometabolic risk in children and adolescents with obesity: a position paper of the Italian Society for Pediatric Endocrinology and Diabetology. *Ital. J. Pediatr.*, 50, 2024,
20. Bertoncini-Silva C, Zingg J, Fassini PG, Suen VMM. et al. Bioactive dietary components-Anti-obesity effects related to energy metabolism and inflammation. *Biofactors*, 49(2), 2023, 297–321.
21. Li G, Meex RCR, Goossens GH. The role of tissue oxygenation in obesity-related cardiometabolic complications. *Rev. Endocr. Metab. Disord.*, 26(1), 2025, 19–30.
22. Valladares AC, Astudillo MA, Drinnon AR, Dowlatshahi S, Kansara A, Shakil J, et al. Medical Management of Obesity: Current Trends and Future Perspectives. *Methodist Debaquey Cardiovasc. J.*, 21, 2025, 62–73.
23. Hao X, Zhu X, Tian H, Lai G, Zhang W, Zhou H, et al. Pharmacological effect and mechanism of orlistat in anti-tumor therapy: A review. *Medicine*, 102(37), 2023, e34671.
24. Młynarska E, Bojdo K, Bulicz A, Frankenstein H, Gašior M, Kustosik N, et al. Obesity as a Multifactorial Chronic Disease: Molecular Mechanisms, Systemic Impact, and Emerging Digital Interventions. *Cell. Mol. Biol.*, 47(10), 2025, 787.
25. Li W, Cai R, Yin B, Zhou Y, Dong X, Li W, et al. Transdermal Semaglutide Administration in Mice: Reduces Body Weight by Suppressing Appetite and Enhancing Metabolic Rate. *Biology*, 14(5), 2025, 575.
26. Ezhilarasan D. Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key? *J. Gastroenterol. Hepatol.*, 40, 2025,
27. Jeromson S, Baranowski B, Akcan M, Waters BD, Eisner K, Bellucci A, et al. Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity. *J. Physiol.*, 2025,
28. Rajesh Y, Sarkar D. Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer. *Int. J. Mol. Sci.*, 22(4), 2021, 2163.
29. Torres Irizarry VC, Jiang Y, He Y, Xu P. Hypothalamic Estrogen Signaling and Adipose Tissue Metabolism in Energy Homeostasis. *Front. Endocrinol.*, 13, 2022, 898139.
30. Šišljagić D, Blažetić S, Heffer M, Vranješ Delač M, Muller A. The Interplay of Uterine Health and Obesity: A Comprehensive Review. *Biomedicines*, 12(12), 2024, 2801.
31. Palacios S, Chedraui P, Sanchez-Borrego R, Coronado P, Simoncini T, Schauding K, et al. Management of obesity in menopause. *Climacteric*, 27(4), 2024, 357–363.
32. Kim MK, Kim HS. An Overview of Existing and Emerging Weight-Loss Drugs to Target Obesity-Related Complications: Insights from Clinical Trials. *Biomol. Ther. (Seoul)*, 33(1), 2025, 5–17.
33. Jeon E, Lee KY, Kim K-K. Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. *J. Obes. Metab. Syndr.*, 32(2), 2023, 106–120.
34. Hawkins LK, Burns L, Swancutt D, Moghadam S, Pinkney J, Tarrant M. et al. Which components of behavioral weight management programs are essential for weight loss in people living with obesity? A rapid review of systematic reviews. *Obes. Rev.*, 25, 2024, Article number not specified.
35. Eliopoulos AG, Gkouskou KK, Tsioufis K, Sanoudou D. et al. A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy. *Front. Nutr.*, 12, 2025, 1524125.
36. Umeh AU, Chima UE, Agbo CE, Chiekwe OS, Eze AE, Nwachuya CA, et al. Pharmacist-led medication therapy management: Impact on healthcare utilization and costs. *Asian J. Pharm. Pharmacol. Sci.*, 4, 2025, 4.
37. Steinl D, Holzerny P, Ruckdäschel S, Föh D, Pataky Z, Peterli R, et al. Cost of overweight, obesity, and related complications in Switzerland 2021. *Front. Public Health*, 12, 2024, 1335115.
38. Hertiš Petek T, Marčun Varda N. Childhood Cardiovascular Health, Obesity, and Some Related Disorders: Insights into Chronic Inflammation and Oxidative Stress. *Int. J. Mol. Sci.*, 25(17), 2024, 9706.
39. Scaglione S, Di Chiara T, Daidone M, Tuttolomondo A. et al. Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk. *Nutrients*, 17(2), 2025, 358.
40. Katrevula A, Kalapala R, Agrawal S, Jagtap N, Chhabra P, Kulkarni AV, et al. Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial. *Indian J. Gastroenterol.*, 2025, Article number not specified.
41. Oppert J-M, Ciangura C, Bellicha A. et al. Health-enhancing physical activity in obesity management: the need to (seriously) go beyond weight loss. *Int. J. Obes.*, 49, 2025, 211–213.
42. Niezgodna N, Chomiuk T, Kasiak P, Mamcarz A, Śliż D. et al. The Impact of Physical Activity on Weight Loss in Relation to the Pillars of Lifestyle Medicine-A Narrative Review. *Nutrients*, 17(6), 2025, 1095.
43. Smyth S, Mulligan K, Rutter E, Harrington L, Hatunic M, Higgins MF. Attitudes of women with gestational diabetes toward diet and exercise: a qualitative study. *J. Matern. Fetal Neonatal Med.*, 36, 2023,

44. Zanini B, Covolo L, Marconi S, Marullo M, Viola GCV, Gelatti U, et al.. Change in eating habits after 2 years of pandemic restrictions among adolescents living in a city in northern Italy: results of the COALESCENT Observational Study (Change amOng ItAlian adoLESCENTs). *BMJ Nutr. Prev. Health*, 7, 2024, 45–53.
45. Anekwe CV, Cano A, Mulligan J, Ang SB, Johnson CN, Panay N, et al. The role of lifestyle medicine in menopausal health: a review of non-pharmacologic interventions. *Climacteric*, 28(5), 2025, 478–496.

Cite this article:

Gokul Veera Ch, Vamshi K, Sowjanya M, Shalini M, Dr. Akila C R. Obesity Pharmacotherapy: Pharmacist's Role in Lifestyle and Drug Management. *International Journal of Pharmacy Practice and Drug Research*, 16(1), 2026, 34-41.



Attribution-NonCommercial-NoDerivatives 4.0 International